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Abstract
Microscopic hematuria is a common feature of patients with 
Alport syndrome, a familial nephropathy due to mutations 
in COL4A3, COL4A4 or COL4A5. These genes encode for α3, 
α4, and α5 type IV collagen polypeptide chains (collagen IV 
α345), crucial for the structural component of the glomerular 
basement membrane. Even patients with mild phenotype, 
namely isolated microhematuria (X-linked females with thin 
basement membrane on electron microscopy or heterozy-
gous carriers of COL4A3 or COL4A4 mutations), can poten-
tially progress to proteinuria and to end-stage renal dis-
ease. Recent pedigree analyses provided evidence for digen-
ic inheritance of Alport syndrome by concomitant 
mutations in COL4A3/COL4A4 or COL4A4/COL4A5. We de-
scribe a Caucasian family with concomitant COL4A3 and CO-
L4A5 mutations, consisting of a novel c.4484A>G COL4A3 
(p.Gln1495Arg) mutation and a previously reported 
c.1871G>A COL4A5 (p.Gly624Asp) mutation. Our segrega-
tion analysis raises the possibility that Alport syndrome re-
sembles also digenic inheritance by COL4A3/COL4A5.
© 2019 S. Karger AG, Basel
Introduction
Microscopic hematuria comprises a clinical entity 
with sporadic or inherited renal diseases due to heteroge-
neous causes. Amongst familial hematuria defects of the 
glomerular basement membrane (GBM) due to collagen 
IV alpha chains abnormalities are the most common. 
These defects of the GBM are characterized by a wide and 
continuous clinical and histopathological spectrum, from 
hematuria to end-stage renal disease, from thin basement 
membrane (TBM) to severe thickening, splitting, and 
complete remodeling of the GBM [1–3]. Moreover, hav-
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ing only a thin basement does not rule out a progressive 
disease [4], supporting the idea that a TBM is not always 
benign. In order to simplify diagnostic terminology and 
improve diagnosis and treatment, Kashtan et al. [5] pro-
posed a new classification system of genetic collagen IV 
α345 molecule disorders, which implicates that the for-
mer term TBM nephropathy is not a nosological entity 
but a histopathological finding. Patients with TBM should 
be redefined as forms of autosomal Alport syndrome 
(e.g., heterozygous mutations in COL4A3 or COL4A4) to 
avoid lack of close follow-up and to optimize appropriate 
treatment. Inheritance is predominantly X-linked (ap-
proximately 80%) and caused by mutations in the  COL4A5 
gene, less cases are inherited in an autosomal recessive or 
autosomal-dominant manner [6–8].
Here, we describe the findings of a novel p.Gln1495Arg 
mutation in COL4A3 (c.4484A>G) and a previously re-
ported p.Gly624Asp mutation in COL4A5 (c.1871G>A) in 
a Caucasian pedigree, causing a thin GBM with not so be-
nign familial hematuria and comprising a complicated Al-
port syndrome and challenge for genetic counselling. Our 
analysis extends our understanding of Alport syndrome as 
a digenic disease [9, 10] caused by concomitant mutations 
of COL4A genes encoding type IV collagen polypeptide 
chains crucial for structural alterations of GBM.
Methods
Patients
All patients were entered into genetic testing after having given 
written informed consent.
DNA Isolation
Mutation analysis was carried out on genomic DNA isolated 
from 200 µL of EDTA-Blood using EZ1 DNA Blood 200 µL Kit, 
QIAGEN EZ1 DNA Blood card, as suggested by Qiagen’s supple-
mentary protocol with EZ1 Advanced XL instrument.
Sanger Sequencing
The coding region and intron-exons boundaries of the  COL4A3 
(Ensembl Transcript ID ENST00000396578) and COL4A5 (En-
sembl Transcript ID ENST00000361603, ENST00000328300, 
ENST00000505728) were amplified by polymerase chain reaction 
(PCR) using flanking intronic primers. Primer details are available 
upon request. The promotor region of COL4A3 was also amplified. 
PCR amplification was performed on GeneAmp PCR System 9700 
(Applied BiosystemsTM). After PCR, the products were enzymati-
cally purified. Direct sequencing of the purified PCR products was 
performed on capillary sequencing devices ABI 3500 Genetic An-
alyzer (Thermo Fisher Scientific, Waltham, MA, USA) using Big-
DyeTM Terminator version 1.1 Cycle Sequencing Kit (Applied Bio-
systemsTM) according to manufacturer’s instructions. NPHS2 
(Podocin) sequencing was performed as previously described [11].
Analysis
For sequence data quality control was used Sequencing Analy-
sis Software version 6.0 (Applied BiosystemsTM). Mutation analysis 
was performed by SeqPilot Software with module SeqPatient (JSI 
Medical Systems Software, version 4.4.0). Sequences were mapped 
to genome hg19, GRCh37). Detected changes of nucleotides and 
amino acids were recorded. The putative pathogenicity of the de-
tected variants was evaluated by Polyphen-2 and MutationT@ster.
Case Presentation
The index patient (Fig. 1, IId, marked with an arrow) 
was a 55-year-old German man, who regularly came for 
follow-up visits to our renal transplant care center. When 
he was 10-year-old, microscopic hematuria and protein-
uria were detected. A renal biopsy was performed, but 
was without any histopathological findings. Electron mi-
croscopy was not performed at that time. He reached 
end-stage renal disease at the age of 47 years and received 
a living organ donation from his wife. Three years after 
renal transplantation, he developed microscopic hematu-
ria and proteinuria up to 4.8 g/g creatinine while his renal 
function remained stable (creatinine of 1.1 mg/dL). A bi-
opsy from his renal transplant showed no pathologic 
findings when using light microscopy, whereas electron 
microscopy showed global foot process effacement lead-
ing to the diagnosis of minimal-change glomerulonephri-
tis. His family history revealed that several family mem-
bers had hematuria in a dominant trait (depicted in 
Fig. 1). His parents (Ia, Ib) had died and also one of his 
brothers (IIe) had died of lung cancer when he was 
33 years old. The index patient’s eldest sister had hema-
turia with proteinuria up to 1.5 g/g creatinine due to bi-
opsy proven diabetic nephropathy. She suffered from di-
abetes mellitus type 1 similarly to one of her daughters. 
The second oldest sister (IIb) had hematuria with a bi-
opsy showing a thin GBM. The index patient’s daughters 
were both affected with microhematuria. In addition, the 
younger one had proteinuria up to 1.7 g/g creatinine, 
which developed during her pregnancy. She also under-
went renal biopsy showing focal segmental glomerulo-
sclerosis (FSGS), which was resistant to treatment with 
steroids and ciclosporin A. Remarkably, except the index 
patient, all family members had normal renal function 
and no hearing or ocular abnormalities. The findings 
prompted us to perform a genetic screening of all family 
members willed to participate. Mutational analysis re-
vealed a hemizygote p.G624D, c.1871 G>A mutation in 
COL4A5 (highlighted with dark gray marks in Fig. 1), a 
milder missense mutation previously reported to be as-




sociated with benign X-linked Alport syndrome [12–14], 
in all tested family members except sibling IIb with a bi-
opsy proven thin GBM. Interestingly, in the latter one, we 
detected a heterozygous mutation p.Gln1495Arg c.4484 
A>G mutation in COL4A3. This mutation was also found 
in several, but not all other family members (highlighted 
with striped marks in Fig. 1). In contrast, we did not de-
tect any mutation in COL4A4 gene. MutationT@ster and 
Polyphen-2 predicted that COL4A3 mutation p.Gl-
n1495Arg c. 4484 A>G is disease causing and possibly 
damaging (score 0.659), respectively. The 37-year-old in-
dividual IIIb showed microhematuria, whereas the 
30-year-old individual IIIc showed proteinuria (Fig. 1). 
No mutations were found in NPHS2 (Podocin) in indi-
viduals IIa, IIb, IId and IIIg. Mutations are depicted in 
Figure 2 comparing the unaffected sibling IIc without any 
pathological findings with sibling IIb with a thin GBM, 
with the index patient with minimal-change glomerulo-
nephritis and with his daughter IIIg with FSGS.
Discussion
This case report describes a family with concomitant 
mutations in both COL4A3 and COL4A5 encoding α3 
and α5 type IV collagen polypeptide chains crucial for the 
structural component of the GBM that comprise Alport 
syndrome. Our findings provide substantial evidence for 
possible digenic inheritance of Alport syndrome by con-
comitant mutations also in this combination of Alport 
genes, as to our knowledge only one single patient has 
been reported so far with concomitant COL4A3/COL4A5 
mutations, that is, a de novo COL4A5 mutation com-
bined with an inherited COL4A3 mutation, which were 
associated with a notably severe phenotype [15].
Individual COL4A3 and COL4A5 DNA Mutations  
in Our Pedigree
Here, we report a novel COL4A3 mutation p.Gl-
n1495Arg c. 4484 A>G associated with the histopatho-
logical finding of a thin GBM in a family with inherited 
Alport syndrome. It is very likely that the COL4A3 
p.Gln1495Arg mutation is pathogenic since the COL4A5 
mutation p.Gly624Asp c. 1871 G>A mutation was not de-
tected in the index patient’s sibling with biopsy proven 
thin GBM. According to the new classification by Kashtan 
et al. [5] that patient finding depicts an autosomal domi-
nant form of Alport syndrome. Interestingly, COL4A3 
p.Gln1495Arg has been previously suspected only as a 
polymorphism or a rare variant of unknown significance 
[7, 16]. In the database of the Exome Aggregation Con-
sortium, the COL4A3 p.Gln1495Arg DNA variant is list-
ed in 6 cases in homozygous form, although the database 
does not contain information on the renal phenotype of 
the 6 cases and does not exclude that this variant may rep-
resent a hypomorphic mutation. Polymorphisms are in-
deed often detected in COL4A3 and COL4A4 which might 
cause non-progressive isolated microscopic hematuria 
that does not result in renal failure (previously called “be-
nign familial hematuria”) [17]. However, based on the 
minor allele frequency (MAF< 0.01, e!GRCh37 Ensembl) 
and the clinical findings of our family, we suggest that the 
novel COL4A3 p.Gln1495Arg c. 4484 A>G variant is a 
pathogenic mutation.
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Fig. 1. Family members with identified het-
ero-/hemizygous COL4A3 and COL4A5 
mutations and their clinical renal pheno-
type. Mutations are indicated with gray or 
striped marks on the right side. ? Individu-




Our data are also in line with the idea that the 
 COL4A5 p.Gly624Asp mutation is a rather benign mu-
tation causing X-linked Alport syndrome [12–14]. In-
terestingly, not all family members with the COL4A5 
p.Gly624Asp mutation had microscopic hematuria, but 
all family members with proteinuria above 1 g/g creati-
nine were detected to have both COL4A3/COL4A5 mu-
tations. Since the MAF of COL4A5 p.Gly624Asp c.4484 
A>G is suspicious high (> 2% in the British population), 
we believe that this DNA variant is causing a very mild 
or even non-pathogenic phenotype. Of note, Pierides et 
al. [18] described this DNA variant as a hypomorphic 
Alport mutation, which can exhibit TBM with micro-
hematuria and late-onset kidney failure in the Hellenic 
population. The prevalence of this variant in the Ger-
man population is unknown. Therefore, it remains un-
clear which mutation caused proteinuria or whether 
both mutations together potentiate each other in phe-
notype, that is, cause a more severe phenotype in 
our  family. Nevertheless, the relatively mild pheno-
type of individuals IIIb and IIIc could depend on their 
relatively young age and/or female gender, the latter 
with  advantageous lyonization in order to express 
 COL4A5.
Possibility of Digenic Inheritance
Using massively parallel sequencing, Mencarelli et al. 
[9] identified 11 patients with Alport syndrome in 6 Euro-
pean countries (except Germany) who had pathogenic 
mutations in 2 of the 3 collagen IV genes. Seven patients 
had a combination of mutations in COL4A3 and COL4A4, 
whereas 4 patients had 1 or 2 mutations in COL4A4 asso-
ciated with mutation in COL4A5 [9]. The authors found 
that individuals with the digenic disease exhibited an in-
termediate phenotype between the autosomal-dominant 
and the autosomal-recessive forms with a severity of renal 
involvement, estimated according to the mean age at onset 
of end-stage renal disease, that is, intermediate between 
those of the classic forms [9]. In the reported pedigrees, the 
“two-locus model” explained the variable expressivity of 
the disease within the same family better than simple Men-
delian inheritance: the different genotypes at 2 loci, rough-
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Fig. 2. Electropherograms showing the p.Gln1495Arg c.4484A>G mutation in COL4A3 found in sibling IIb, in-
dex patient IId, and his daughter IIIg (a) and p.Gly624Asp c.1871G>A mutation in COL4A5 detected in index 



















ly equal in importance, can explain the differences in age 
at onset of renal failure and in the severity of the symp-
toms. Similar findings were reported in a Chinese family 
with COL4A3 and COL4A4 digenic mutations mimicking 
an autosomal dominant inheritance [10]. Together, the 
results indicate that Alport syndrome is under digenic 
control by COL4A3/COL4A4 and COL4A4/COL4A5.
There is only one report on a patient with Alport 
syndrome with an inherited COL4A3 mutation com-
bined with a de novo COL4A5 mutation [15]. Our study 
reports the findings of at least 6 more cases on a pedi-
gree with 2 concomitant COL4A3/COL4A5 mutations. 
Since the patient in [15] and our index patient exhib-
ited a more severe phenotype, the findings raise the 
possibility of digenic inheritance of Alport syndrome by 
mutations also in COL4A3 and COL4A5. Since genetic 
testing is only performed in families with suspect-
ed GBM disease due to collagen IV alpha chains abnor-
malities, the prevalence of these mutations in sub-
jects without a clinical phenotype is unknown. Never-
theless, on a conceptual level, our findings support 
the  view that Alport syndrome is a genetic collagen 
IV α345 molecule disorder under digenic control by all 
3 COL4A3/4/5 gene combinations [5], that is, by 
COL4A3/COL4A4 [9], COL4A4/COL4A5 [9], and 
COL4A3/COL4A5 (this study).
Alport Syndrome and Podocin Mutations
The association of FSGS with TBM has been reported, 
and it was speculated that either FSGS is secondary to TBM 
or that a coinherited glomerulopathy causes progressive 
renal disease [19–21]. Hypomorphic podocin variants may 
act as adverse genetic modifiers when coinherited with 
COL4A3/A4 mutations, thus predisposing to FSGS and se-
vere kidney failure [22, 23]. Our sequencing data argue 
against a possible role of NPHS2 (Podocin) mutations in 
our family. Recently, Gast et al. [24] demonstrated that 
COL4A3/COL4A4 and COL4A5 mutations might cause 
FSGS in adulthood. In contrast, the hypothesis of a coexist-
ing glomerulopathy was confirmed in a retrospective anal-
ysis of 658 renal biopsies, where TBM was usually associ-
ated with a benign phenotype and with a worse renal out-
come only in the presence of another glomerulopathy [25].
In conclusion, our findings expand knowledge regard-
ing causative COL4A3 and COL4A5 mutations of GBM 
disease due to collagen IV alpha chains abnormalities. 
The identification of novel mutations in patients with Al-
port syndrome, including histopathological findings of a 
thin GBM, is crucial to elucidate its pathogenic role and 
relevance in patients with familial hematuria.
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